110 related articles for article (PubMed ID: 35261801)
21. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
22. Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
Kobayashi N; Hashimoto H; Kamimaki C; Nagasawa R; Tanaka K; Kubo S; Katakura S; Chen H; Hirama N; Ushio R; Aoki A; Nakashima K; Teranishi S; Manabe S; Watanabe H; Horita N; Watanabe K; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2020 Aug; 11(8):2125-2129. PubMed ID: 32495514
[TBL] [Abstract][Full Text] [Related]
23. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
Sun HY; Du ST; Li YY; Deng GT; Zeng FR
World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
[TBL] [Abstract][Full Text] [Related]
24. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
26. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
[TBL] [Abstract][Full Text] [Related]
27. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.
Xu L; Chen Y; Mayakonda A; Koh L; Chong YK; Buckley DL; Sandanaraj E; Lim SW; Lin RY; Ke XY; Huang ML; Chen J; Sun W; Wang LZ; Goh BC; Dinh HQ; Kappei D; Winter GE; Ding LW; Ang BT; Berman BP; Bradner JE; Tang C; Koeffler HP
Proc Natl Acad Sci U S A; 2018 May; 115(22):E5086-E5095. PubMed ID: 29764999
[TBL] [Abstract][Full Text] [Related]
28. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
30. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
31.
Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
[TBL] [Abstract][Full Text] [Related]
32. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
33. Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor.
Gao Y; Zhang J; Li J; Song S; Zhang S; Liu Q; Wang X; Zhao J; Xia C; Xiao Y; Liu T
Eur J Med Chem; 2023 Sep; 257():115478. PubMed ID: 37269669
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells.
Padmanabhan J; Saha B; Powell C; Mo Q; Perez BA; Chellappan S
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359807
[TBL] [Abstract][Full Text] [Related]
35. Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330].
Choi JE; Verhaegen ME; Yazdani S; Malik R; Harms PW; Mangelberger D; Tien J; Cao X; Wang Y; Cieślik M; Gurkan J; Yazdani M; Jing X; Juckette K; Su F; Wang R; Zhou B; Apel IJ; Wang S; Dlugosz AA; Chinnaiyan AM
Neoplasia; 2024 May; 51():100995. PubMed ID: 38574506
[No Abstract] [Full Text] [Related]
36. Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer.
Yao Z; Song P; Jiao W
Front Pharmacol; 2024; 15():1383580. PubMed ID: 38681203
[TBL] [Abstract][Full Text] [Related]
37. mitoSplitter: A mitochondrial variants-based method for efficient demultiplexing of pooled single-cell RNA-seq.
Lin X; Chen Y; Lin L; Yin K; Cheng R; Lin X; Wang X; Guo Y; Wu Z; Zhang Y; Li J; Yang C; Song J
Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2307722120. PubMed ID: 37725654
[TBL] [Abstract][Full Text] [Related]
38. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
[TBL] [Abstract][Full Text] [Related]
39. Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells.
Wang Q; Li B; Zhang W; Li Z; Jiang B; Hou S; Ma S; Qin C
Front Chem; 2023; 11():1121724. PubMed ID: 36733715
[TBL] [Abstract][Full Text] [Related]
40. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]